Stockreport

ChemoCentryx’s Novel Small Molecule Antagonists of Checkpoint Inhibitors and Chemokine Receptors to be Presented at the American Association for Cancer Research (AACR) Tumor Immunology and...

ChemoCentryx, Inc.  (CCXI) 
Last chemocentryx, inc. earnings: 3/10 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.chemocentryx.com
PDF -- Studies highlight CCX4503, a unique small molecule inhibitor of immune checkpoint molecules PD-1/PD-L1, demonstrates anti-tumor efficacy in vivo ---- Company’s studie [Read more]